Teva FDA Friday, May 28, 1976 -0.40 Negative

FDA Approves PROGLYCEM — Teva Pharmaceuticals USA, Inc.

Teva Pharmaceuticals USA, Inc. has confirmed the continued commercialization of the FDA-approved oral insulin secretion enhancer PROGLYCEM (diazoxide), developed decades ago. The firm faces potential earnings pressure and downward pricing pressure as generic alternatives likely erode sales in this niche market.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed